-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-3795 in Von Hippel-Lindau Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-3795 in Von Hippel-Lindau Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-3795 in Von Hippel-Lindau Syndrome Drug Details: MK-3795 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulixertinib in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulixertinib in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulixertinib in Neurofibromatoses Type I (Von Recklinghausen's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAS-004 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAS-004 in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAS-004 in Neurofibromatoses Type I (Von Recklinghausen's...
-
Product Insights
Likelihood of Approval Analysis for Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Overview How likely is it that the drugs in Neurofibromatoses Type I (Von Recklinghausen's Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neurofibromatoses Type I (Von Recklinghausen's Disease) Overview Neurofibromatosis...
-
Product Insights
NewVon Willebrand Disease (vWD) – Drugs In Development, 2024
Empower your strategies with our Von Willebrand Disease (vWD) – Drugs In Development, 2024 report and make more profitable business decisions. Von Willebrand Disease (vWD) is a very common bleeding disorder that can be either inherited or acquired. It is caused by a deficiency of pro-von Willebrand factor which is a glycoprotein that plays a major role in hemostasis. This condition is classified as type-1, type-2, and acquired. People with this disease experience excess bleeding or a long duration for the...
-
Product Insights
NewNeurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2024
Empower your strategies with our Neurofibromatoses Type I (Von Recklinghausen's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Pheochromocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Pheochromocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Pheochromocytoma Drug Details: Belzutifan (Welireg) is an anti-cancer agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Gastrointestinal Stromal Tumor (GIST) Drug Details: Belzutifan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Pancreatic Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Pancreatic Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Pancreatic Tumor Drug Details: Belzutifan (Welireg) is an anti-cancer...